These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32946200)

  • 1. Empagliflozin inhibits Na
    Trum M; Riechel J; Lebek S; Pabel S; Sossalla ST; Hirt S; Arzt M; Maier LS; Wagner S
    ESC Heart Fail; 2020 Dec; 7(6):4429-4437. PubMed ID: 32946200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF.
    Trum M; Riechel J; Schollmeier E; Lebek S; Hegner P; Reuthner K; Heers S; Keller K; Wester M; Klatt S; Hamdani N; Provaznik Z; Schmid C; Maier L; Arzt M; Wagner S
    Cardiovasc Res; 2024 Jul; 120(9):999-1010. PubMed ID: 38728438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
    Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
    Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcolemmal Na+/H+ exchanger activity and expression in human ventricular myocardium.
    Yokoyama H; Gunasegaram S; Harding SE; Avkiran M
    J Am Coll Cardiol; 2000 Aug; 36(2):534-40. PubMed ID: 10933369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells.
    Chen S; Schumacher CA; Van Amersfoorth SCM; Fiolet JWT; Baartscheer A; Veldkamp MW; Coronel R; Zuurbier CJ
    Front Physiol; 2023; 14():1179131. PubMed ID: 37565139
    [No Abstract]   [Full Text] [Related]  

  • 6. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
    Uthman L; Nederlof R; Eerbeek O; Baartscheer A; Schumacher C; Buchholtz N; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
    Cardiovasc Res; 2019 Aug; 115(10):1533-1545. PubMed ID: 30649212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
    Chen S; Wang Q; Bakker D; Hu X; Zhang L; van der Made I; Tebbens AM; Kovácsházi C; Giricz Z; Brenner GB; Ferdinandy P; Schaart G; Gemmink A; Hesselink MKC; Rivaud MR; Pieper MP; Hollmann MW; Weber NC; Balligand JL; Creemers EE; Coronel R; Zuurbier CJ
    Basic Res Cardiol; 2024 Jul; ():. PubMed ID: 39046464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis.
    Chung CC; Lin YK; Chen YC; Kao YH; Yeh YH; Trang NN; Chen YJ
    Cardiovasc Diabetol; 2023 Feb; 22(1):27. PubMed ID: 36747205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of the plasma membrane Na+/H+ exchanger NHE1 by sustained intracellular acidosis. Evidence for a novel mechanism mediated by the ERK pathway.
    Haworth RS; McCann C; Snabaitis AK; Roberts NA; Avkiran M
    J Biol Chem; 2003 Aug; 278(34):31676-84. PubMed ID: 12791686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin Ameliorates Ouabain-Induced Na
    Peng X; Li L; Lin R; Wang X; Liu X; Li Y; Ma C; Ruan Y; Liu N
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):461-469. PubMed ID: 34982348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sgk1-dependent stimulation of cardiac Na+/H+ exchanger Nhe1 by dexamethasone.
    Voelkl J; Pasham V; Ahmed MS; Walker B; Szteyn K; Kuhl D; Metzler B; Alesutan I; Lang F
    Cell Physiol Biochem; 2013; 32(1):25-38. PubMed ID: 23860121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na
    Baker HE; Tune JD; Mather KJ; Blaettner BS; Clark HE; Li F; Li X; Kowala MC; Fliegel L; Goodwill AG
    Int J Cardiol; 2022 Sep; 363():138-148. PubMed ID: 35753619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression.
    Abdulrahman N; Ibrahim M; Joseph JM; Elkoubatry HM; Al-Shamasi AA; Rayan M; Gadeau AP; Ahmed R; Eldassouki H; Hasan A; Mraiche F
    Mol Cell Biochem; 2022 Jun; 477(6):1865-1872. PubMed ID: 35334035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin decreases myocardial cytoplasmic Na
    Baartscheer A; Schumacher CA; Wüst RC; Fiolet JW; Stienen GJ; Coronel R; Zuurbier CJ
    Diabetologia; 2017 Mar; 60(3):568-573. PubMed ID: 27752710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crucial role for sensory nerves and Na/H exchanger inhibition in dapagliflozin and empagliflozin-induced arterial relaxation.
    Forrester EA; Benítez-Angeles M; Redford KE; Rosenbaum T; Abbott GW; Barrese V; Dora K; Albert AP; Dannesboe J; Salles-Crawley I; Jepps TA; Greenwood IA
    Cardiovasc Res; 2024 Jul; ():. PubMed ID: 39056245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Na+/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model.
    Baartscheer A; Schumacher CA; van Borren MM; Belterman CN; Coronel R; Fiolet JW
    Cardiovasc Res; 2003 Mar; 57(4):1015-24. PubMed ID: 12650879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic inhibition of na(+)/h(+)-exchanger in the heart.
    Baartscheer A
    Curr Vasc Pharmacol; 2006 Jan; 4(1):23-9. PubMed ID: 16472174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular pH regulatory mechanism in human atrial myocardium: functional evidence for Na(+)/H(+) exchanger and Na(+)/HCO(3)(-) symporter.
    Loh SH; Chen WH; Chiang CH; Tsai CS; Lee GC; Jin JS; Cheng TH; Chen JJ
    J Biomed Sci; 2002; 9(3):198-205. PubMed ID: 12065894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.
    Jiang K; Xu Y; Wang D; Chen F; Tu Z; Qian J; Xu S; Xu Y; Hwa J; Li J; Shang H; Xiang Y
    Protein Cell; 2022 May; 13(5):336-359. PubMed ID: 33417139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced activity of the myocardial Na+/H+ exchanger contributes to left ventricular hypertrophy in the Goto-Kakizaki rat model of type 2 diabetes: critical role of Akt.
    Darmellah A; Baetz D; Prunier F; Tamareille S; Rücker-Martin C; Feuvray D
    Diabetologia; 2007 Jun; 50(6):1335-44. PubMed ID: 17429605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.